There are more treatments today than ever before to help people with ongoing conditions manage their physical symptoms. But even with these medical advances, a diagnosis of myelodysplastic syndromes ...

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r ...

Dr. Shaal Patel, a board certified physician in hematology, oncology, and internal medicine, spoke with Healthline about how myelodysplastic syndromes (MDS) can benefit from supportive therapy, ...

Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS. “You have myelodysplastic syndrome,” the oncologist told me soberly.

Luspatercept shows higher efficacy than ESAs in increasing hemoglobin levels and sustaining improvement in LR-MDS patients. Patients treated with luspatercept achieve faster and more sustained red ...

Dr. Markku Jalkanen, CEO of Faron, remarked on the significance of the EMA's support, emphasizing the company's commitment to developing bexmarilimab as a potentially new and effective therapy for MDS ...